Investigational drug · Phase 3
Precemtabart tocentecan
Also called: Precem-TcT, M9140
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Precemtabart tocentecan"
First trial start
2025
Jan 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Precemtabart tocentecan", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Colorectal Cancer
- Solid Tumors
- Gastric Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Pancreatic Cancer
- Pancreatic Ductal Adenocarcinoma (PDAC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Precemtabart tocentecan" as an intervention, largest first.
- A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)Pivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07549412 · 1,020 participants (planned) · Start May 6, 2026 · Primary completion Oct 16, 2029
Drug: Precemtabart tocentecan; Bevacizumab and 1 more · For: Metastatic Colorectal Cancer
Sites: San Francisco, California; Lone Tree, Colorado; Fort Myers, Florida · 116 sites in all
- Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)Active, not recruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT05464030 · 220 participants · Start Aug 4, 2022 · Primary completion Oct 23, 2026
Drug: M9140; M9140 and 4 more · For: Colorectal Cancer
Sites: Encinitas, California; Fresno, California; Providence, Rhode Island · 35 sites in all
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT06710132 · 184 participants · Start Jan 29, 2025 · Primary completion Dec 23, 2027
Drug: M9140 · For: Solid Tumors; Gastric Cancer; Non-Small Cell Lung Cancer (NSCLC) and 2 more
Sites: Santa Monica, California; Santa Rosa, California; Washington D.C., District of Columbia · 81 sites in all
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT06806046 · 12 participants · Start Dec 20, 2024 · Primary completion Sep 23, 2026
Drug: M9140 · For: Solid Tumors; Colorectal Cancer
Sites: Beijing, China; Guangzhou, China; Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial.
Kopetz S, Boni V, Kato K, et al. · Nat Med 2025
- The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients-The Putative Mechanism Behind ILD.
Sloot WN, Bertotti E, Onidi M, et al. · Int J Toxicol 2025
Also in development for Metastatic Colorectal Cancer
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
- CyclophosphamidPhase 33 trials
Alentis Therapeutics AG · Glomerulonephritis Rapidly Progressive, Diffuse Large B-Cell Lymphoma (DLBCL), Metastatic Colorectal Cancer
- CTX-009Phase 32 trials
Compass Therapeutics · Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer
- AB928Etrumadenant, ETRUMAPhase 24 trials
Arcus Biosciences, Inc. · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.